Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

被引:0
作者
Johnna Perdrizet
Emily K. Horn
Winniefer Nua
Judith Perez-Peralta
Jennifer Nailes
Jaime Santos
Anna Ong-Lim
机构
[1] Pfizer Inc.,Global Health Economics and Outcomes Research
[2] Pfizer Inc.,Research Institute for the Health Sciences
[3] University of the East Ramon Magsaysay Memorial Medical Center,Infectious Diseases Section
[4] Philippine Children’s Medical Center,Infectious and Tropical Disease, Department of Pediatrics
[5] College of Medicine-Philippine General Hospital,undefined
[6] University of the Philippines Manila,undefined
来源
Infectious Diseases and Therapy | 2021年 / 10卷
关键词
Cost-effectiveness; Economic evaluation; Otitis media; Pediatric; Philippines; Pneumococcal conjugate vaccine; Pneumococcal disease; Pneumonia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2625 / 2642
页数:17
相关论文
共 65 条
[1]  
Wahl B(2018)Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect Dis 18 1191-1210
[2]  
O'Brien KL(2018)Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 Lancet Glob Health 6 e744-e757
[3]  
Greenbaum A(2021)A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006–2019) Expert Rev Vaccines 10 156-166
[4]  
Wang BC(2015)Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines PLoS ONE 3 560-569
[5]  
Chaiyakunapruk N(2014)Cost-effectiveness analysis of pneumococcal vaccination with the pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines Value Health Reg Issues 15 353-371
[6]  
Zhu S(2021)Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL®) Hum Vaccine Immunother 7 127-136
[7]  
Haasis MA(2019)Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico Hum Vaccine Immunother 21 1765-1778
[8]  
Ceria JA(2018)Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada Infect Dis Ther 10 909-918
[9]  
Kulpeng W(2021)Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study Lancet Infect Dis 17 1162-1172
[10]  
Teerawattananon Y(2021)Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium Infect Dis Ther 17 305-324